## 1.6 Product Information

# **1.6.1 Prescribing Information (Summary of Product Characteristics)**

## **Note:**

- 1) We do not have a package insert in the SmPc format as yet. We are still waiting for approval thereof from the South African Health Products Regulatory Authority (SAHPRA).
- 2) We also do not have an approved patient information leaflet (PIL) yet. This is also pending SAHPRA approval.
- 3) We have however included the currently approved South African Package Insert which is also what can be found in the product.

# **BENYLIN® DRY COUGH**

## **SCHEDULING STATUS:**



## PROPRIETARY NAME (AND DOSAGE FORM):

BENYLIN® Dry Cough (syrup)

#### **COMPOSITION:**

Each 5 ml syrup contains:

Dextromethorphan hydrobromide 15 mg

Preservative: Sodium Benzoate 0,5 % m/v

Sugar-free Alcohol-free

**Other ingredients:** sorbitol, glycerine, propylene glycol, sodium citrate hydrous, sodium carboxymethylcellulose, sodium cyclamate, citric acid hydrous, water purified, saccharin sodium, menthol, D & C YELLOW NO. 10, F D & C RED NO. 40, F D & C BLUE NO. 1 and raspberry flavour.

#### PHARMACOLOGICAL CLASSIFICATION:

A: 10.1 Antitussives and Expectorants

## PHARMACOLOGICAL ACTION:

Dextromethorphan is a centrally acting cough suppressant. It acts by elevating the threshold for coughing.

## **INDICATIONS:**

BENYLIN® Dry Cough is indicated for the symptomatic relief of non-productive cough.

#### **CONTRA-INDICATIONS:**

Hypersensitivity to dextromethorphan or to any of the ingredients.

Contra-indicated in patients with asthma and hepatic dysfunction.

BENYLIN® Dry Cough should not be given to children under 5 years of age.

Safety in pregnancy and lactation has not been established.

(SEE PREGNANCY AND LACTATION)

#### **WARNINGS:**

BENYLIN<sup>®</sup> Dry Cough should not be taken for persistent cough, which occurs with smoking, asthma, emphysema or where cough is accompanied by excessive secretions except under the advice and supervision of a doctor. A persistent cough may be a sign of a serious condition. If cough persists for more than one week,

tends to recur or is accompanied by high fever, rash or persistent headache, consult a doctor.

#### **INTERACTIONS:**

Concomitant administration with central nervous system depressants may potentiate central nervous system depressant effects. Concurrent use with monoamine oxidase inhibitors may cause excitation, hypertension and hyperpyrexia.

## PREGNANCY AND LACTATION:

## Pregnancy:

BENYLIN® Dry Cough is not recommended in pregnancy.

#### Lactation:

BENYLIN® Dry Cough should not be used by nursing mothers, as there is no information to support the secretion of dextromethorphan into breast milk

#### DOSAGE AND DIRECTIONS FOR USE:

Adults: One medicine measure (5 ml) every four hours, or two medicine measures (10

ml) every six to eight hours.

**Children 5 to 12 years**: Half to one medicine measure (2,5 ml – 5 ml) every six to eight

hours.

Children below 5 years of age: Not recommended

## SIDE-EFFECTS AND SPECIAL PRECAUTIONS:

Dextromethorphan may cause dizziness, gastro-intestinal disturbances, drowsiness, nausea and vomiting, and stomach pain. Respiratory depression is expected to occur at very high doses.

## **Special Precautions:**

Persistent coughs should be investigated by a doctor for the possible underlying cause.

## KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

Excitation and confusion may occur after overdosage.

#### Treatment:

Symptomatic and supportive.

## **IDENTIFICATION:**

Dark brown syrup with a faint odour of menthol and raspberries.

## PRESENTATION:

Bottles containing 100 ml and 200 ml, with a plastic measuring cup.

## STORAGE INSTRUCTIONS:

Store in a cool place (at or below 25°C).

KEEP OUT OF REACH OF CHILDREN.

## **REGISTRATION NUMBER:**

Z/10.1/5

## NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:

Johnson & Johnson (Pty) Ltd.

241 Main Road

RETREAT

7945

South Africa

## DATE OF PUBLICATION OF THIS PACKAGE INSERT:

02 March 2012

# **EXPORT REGISTRATION DETAILS**

Botswana: BOT9800287 S3

Ghana: FDA/SD.133-1062

Kenya: H2001/0370

Malawi: PMPB/PL 353/5

NAFDAC Reg. No.: B4-7110

Tanzania: TAN 00,927 R05F WAR

Uganda: 1651/25/97

Zambia: 082/047 P

Zimbabwe: 2000/22.2.5/3769 P